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Abstract Autophagy, a catabolic process involved in the
sequestration and lysosomal degradation of cytoplasmic
contents, is crucial for cellular homeostasis. The current
literature supports that autophagy plays diverse roles in the
development, maintenance, and progression of tumors.
While genetic evidence indicates autophagy functions as a
tumor suppressor mechanism, it is also apparent that
autophagy can promote the survival of established tumors
under stress conditions and in response to chemotherapy. In
this review, we discuss the mechanisms and the evidence
underlying these multifaceted roles of autophagy in
tumorigenesis, the prospects for targeting autophagy in
cancer therapy, and overview the potential markers that
may be utilized to reliably detect autophagy in clinical
settings.
Keywords Autophagy.Cancer.Genome instability.Cell
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Introduction
Macroautophagy (autophagy) is a tightly regulated self-
digestive process in which cytoplasmic contents and organ-
elles are sequestered within double-membrane vesicles, called
autophagosomes, and delivered to the lysosome for degrada-
tion and recycling. Autophagy is regulated by a limited
number of highly conserved genes called ATGs (for
AuTophaGy gene). Although originally identified in yeast
[1], there have been numerous recent breakthroughs in
mammals demonstrating how autophagy critically regulates
key physiological and pathological processes. Autophagy
serves vital housekeeping functions in cells, including the
turnover of damaged organelles and long-lived proteins [2].
Furthermore, the bulk degradation of cellular material
through autophagy allows cells to recycle both nutrients
and energy during starvation and stress [3]. Thus, autoph-
agy is proposed to function as a “battery” that buys cells
valuable time, allowing them to survive if the stressor is
removed in a timely manner. The indispensable contribu-
tion of cellular autophagy to physiological homeostasis has
been demonstrated by studies in which mice with genetic
deletion of critical ATGs die within a day after birth [4, 5].
On the other hand, an excessive level of autophagy has
been proposed to promote cell death due to the over-
consumption of critical cellular constituents [6]; this process
has been termed ATG-dependent or type II-programmed cell
death.
Overall, the malfunctioning of this cellular self-eating
has been linked to a wide range of pathological conditions
including neurodegenerative diseases, pathogen infection,
and cancer [7]. Autophagy is activated in response to
multiple stresses during cancer progression, such as nutrient
starvation, the unfolded protein response (UPR) (endoplas-
mic reticulum (ER) stress), and hypoxia; in addition, it is
observed upon treatment of cancers with a wide spectrum
of cytotoxic and targeted chemotherapeutic agents [8, 9]. In
this review, we will summarize the current understanding of
the role of autophagy in tumorigenesis, the current status
and opportunities of autophagy manipulation in cancer
therapy and also discuss the need for identification of
suitable markers of autophagy in clinical settings.
This article is published as part of the Special Issue on Autophagy.
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Autophagosome formation Autophagy is a multi-step pro-
cess characterized by the induction, nucleation, extension,
and completion of an isolation membrane (also termed the
phagophore) to form an organelle called the autophago-
some; cytosolic proteins and organelles sequestered within
the autophagosome are subsequently delivered to the
lysosome for degradation (Fig. 1). Studies conducted in
yeast have revealed over 30 ATG genes involved in this
process, many of whose mammalian orthologues have also
been identified.
ULK complex In mammals, the induction of autophagy
requires the unc-51-like kinase (ULK; ATG1 in yeast),
which exists in a large complex with mATG13 and FIP200
that is regulated by mammalian target of rapamycin
(mTOR) [10]. Although it bears no structural homology to
the yeast counterpart, FIP200 has been proposed to be a
functional orthologue of yeast ATG17 during autophago-
some induction [11]. Interestingly, truncation mutants of
this protein have been described in breast cancer patients
[12].
There are at least three different ULK proteins involved
in different aspects of autophagy. However, ULK1 and
ULK2 bear highest similarity to yeast ATG1. Under
nutrient rich conditions, the ULK complex interacts with
mTORC1 and remains inactivated by mTORC1-mediated
phosphorylation of ULK1 and ULK2. However, upon
nutrient deprivation, mTORC1 dissociates from the com-
plex causing dephosphorylation and activation of ULK1
and ULK2, which can then phosphorylate and activate
mATG13 and FIP200, leading to subsequent localization of
the activated ULK complex to the phagophore [13].
However, the substrates of the ULK complex and how it
regulates the autophagic machinery are not entirely known.
Remarkably, the genetic deletion of ULK1 in mice has been
demonstrated to have minimal effects on the initial
formation or completion of the autophagosome; this lack
of phenotype may arise from compensation by other ULK
isoforms [14]. Instead, cells lacking ULK1 demonstrate an
increase in mitochondrial mass, resulting from the defective
clearance of mitochondria via autophagy [14].
Class III phosphatidylinositol 3-kinase complex A Class III
phosphatidylinositol 3-kinase (PI3K) complex is necessary
for the formation of phosphatidylinositol 3-phosphate
(PI3P), which is essential for the early stages of nucleation
of the phagophore. The PI3K core complex consists of the
PI3K protein Vps34, beclin1, and p150 [15]. Though the
exact mechanism is not yet clear, it is evident that the core
complex localizes to the phagophore and facilitates recruit-
ment of subsequent ATGs. Recent studies have identified
various binding partners of beclin1, including ultraviolet
(UV) radiation resistance-associated gene (UVRAG) [16,
17], ATG14L/Barkor [18, 19], and Ambra1 [20] which all
positivelyregulatebeclin1 activityand regulatedifferentsteps
of autophagosome formation and maturation. Moreover,
another molecule named Rubicon (RUN domain and
cysteine-rich domain containing, Beclin1-interacting protein)
has been uncovered as a negative regulator of beclin1 [18],
which binds to the UVRAG–beclin complex and regulates
latestagesofautophagy, more specifically, the lateendosomal
and lysosomal maturation process.
Fig. 1 Schematic depiction of the autophagy pathway. Autophagy is a
multi-step process characterized by the induction, nucleation, exten-
sion, and completion of an isolation membrane (phagophore). The
initiation of autophagy is regulated by the ULK complex. Nucleation
of the phagophore is regulated by the Class III PI3K complex, which
consists of Vps34, Beclin1, p150, and ATG14. Membrane elongation
requires two ubiquitin-like systems that mediate the formation of
ATG12-ATG5 and PE-conjugated ATG8. The completed autophago-
some, along with sequestered cargo, ultimately fuses with the
lysosome. The resulting autolysosome is a single membrane-bound
acidic vesicle where the contents are digested by lysosomal hydrolases
and recycled. Further details are provided in the text
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phagophore membrane elongation requires two ubiquitin-
like systems [21, 22]. The first involves the conjugation of
ATG5 to ubiquitin-like ATG12 via E1- and E2-like
activities of ATG7 and ATG10, respectively. The ATG5–
ATG12 complex binds ATG16 and forms a large multimeric
complex called the ATG16L complex, which localizes on the
outer surface of the extending autophagosomal membrane.
The second conjugation system involves cleavage of the
ubiquitin-like molecule, ATG8, by the protease ATG4 to
expose a C-terminal glycine residue required for subsequent
activation and conjugation reactions. Ultimately, ATG8 is
conjugated to the lipid phosphotidylethanolamine (PE) via
ATG7 and E2-like ATG3, and is subsequently recruited to
both the outer and inner surfaces of the autophagosomal
membrane. Several mammalian orthologues to ATG8 have
been identified, of which the best characterized is
microtubule-associated protein light chain 3 (MAPLC3 or
LC3) [23]. Importantly, the ATG16L complex with ATG5–
ATG12 has been demonstrated to serve as an E3 that
promotes the lipidation of ATG8/LC3 [24, 25]. Moreover,
recent evidence suggests that ATG8/LC3 conjugation system
can also regulate the ATG16L complex because in ATG3-
deficient mice, where no detectable LC3 lipidation is present,
there is marked impairment of ATG5-ATG12 conjugation
[26]. To date, these conjugation reactions have been
proposed to be uniquely devoted to the process of
autophagosome formation, presumably by promoting mem-
brane fusion and biogenesis during the elongation of the
phagophore; as a result, they have been viewed as specific
drug targets to potentially modulate autophagy in cancer
[27].
Autophagosome maturation The completion of the auto-
phagosome membrane is followed by its subsequent fusion
with the lysosome via the action of the lysosomal proteins
LAMP1 and LAMP2, as well as Rab7 and UVRAG [28].
The resulting autolysosome is a single membrane-bound
acidic vesicle where the contents are digested and recycled
by lysosomal hydrolases (e.g., cathepsins). These single-
membrane autolysosomes, filled with degraded cytoplasmic
material, are most commonly observed by electron micros-
copy following the induction of autophagy in response to
diverse stimuli.
Regulation of autophagy by mammalian target
of rapamycin
Significant progress has been made over the past years in
determining the molecular regulators of autophagy. For
detailed understanding of autophagic regulators, additional
reading is recommended [29]. Here, we principally focus
on the role of the mTOR pathway in autophagy regulation.
The serine/threonine kinase mTOR plays a pivotal role
in maintaining the balance between cell growth and
autophagy in response to growth factor signaling, nutrient
status, and stress. mTOR exists in two complexes:
mTORC1 (consisting of mTOR, GβL, raptor, Deptor,
PRAS40), which is sensitive to rapamycin, and mTORC2
(consisting of mTOR, GβL, rictor, Sin1, PRR5, Deptor)
[30]. Activated mTORC1 promotes mRNA translation by
activating S6K and inhibiting 4EBP1; in addition, it also
inhibits autophagy by phosphorylating the ATG13-ULK-
FIP200 complex [31]. Regulation of mTORC1 activity in
response to diverse stimuli is primarily regulated by the
tuberous sclerosis complex (TSC) proteins [32]. TSC2, in a
complex with TSC1, acts as a GTPase activating protein for
the small GTPase Ras homolog enriched in brain (Rheb)
that activates mTORC1 in its GTP-bound form [33].
The role of mTOR in mediating growth factor signaling
is primarily in response to the class I PI3K-protein kinase B
(Akt) pathway [34]. Activated growth factor receptor
stimulates PI3K to convert phosphotidylinositol 4,5-
bisphosphate to phosphotidylinositol 3,4,5-trisphosphate,
leading to the recruitment of phosphatidylinositide-
dependent protein kinase 1 (PDK1) and Akt to the plasma
membrane followed by phosphorylation and activation of
Akt by PDK1. Activated Akt then phosphorylates TSC2
and prevents TSC complex formation and thus leads to
mTOR activation. Though the role of mTORC2 in
autophagy is not clearly delineated, it is important to
recognize that mTORC2 activates Akt; because Akt
positively regulates mTORC1 activity, one can speculate
that mTORC2 also negatively regulates autophagy [35].
During tumorigenesis, constitutive activation of the PI3K
pathway often leads to increased mTORC1 activation,
presumably resulting in autophagy inhibition. In fact,
inhibition of Akt kinase activity has been recently shown
to induce autophagy levels [36]. On the other hand,
overexpression of tumor suppressor phosphatase and tensin
homolog (PTEN), the negative regulator of PI3K/AKT
pathway, induces autophagy [37].
mTOR is also a critical sensor of cellular energy and
nutrient status. Reduced ATP production during nutrient
deprivation results in an elevated AMP/ATP ratio and
activates the energy-sensing serine/threonine kinase 11
(LKB1)-adenosine monophosphate–activated protein ki-
nase (AMPK) signaling axis. AMPK mediates the phos-
phorylation of TSC, leading to inactivation of mTORC1
and induction of autophagy [38]. AMPK can also directly
phosphorylate Raptor and thus regulate mTORC1 in a
TSC-independent manner [39]. Moreover, the cellular
amino acid pool, especially branched chain amino acids,
critically regulates mTOR activity. A recent study revealed
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SLC1A5 followed by its rapid efflux via the bidirectional
transporter SLC7A5/SLC3A2, which is responsible for
simultaneous L-glutamine efflux and leucine import, results
in mTORC1 activation. Thus, loss of SLC1A5 inhibits cell
growth and activates autophagy presumably due to inhibi-
tion of leucine uptake into cells [40].
Finally, mTOR also serves as an important sensor of
cellular stress. Regulated in development and DNA damage
response 1 (REDD1) is induced by hypoxia and leads to
mTORC1 inhibition by regulating the TSC complex [41].
Moreover, the tumor suppressor protein p53, which is
induced in response to diverse genotoxic stress, has also
been shown to promote transcription of various negative
regulators of the mTOR pathway, such as AMPKβ, TSC2,
and PTEN [42, 43]. Furthermore,sestrin,whichisinducedin
response to DNA damage and oxidative stress in a p53-
dependent manner, was recently shown to inhibit mTORC1
activity via AMPK activation [44]. Additional studies
revealed that sestrin2 is indeed required for autophagy
induction in response to various stress inducers, including
nutrient starvation and rapamycin [45], thereby further
establishing the link between p53, mTORC1, and autophagy.
However, it is important to recognize that the role of p53 in
autophagy regulation is not straightforward, because it can
also promote autophagy in an mTOR-independent manner
via the transcriptional upregulation of its downstream target
damage-regulated autophagy modulator (DRAM) [46].
Though additional pathways exist, mTOR, which is
positioned at the crossroads of various critical signaling
pathways, serves as a focal point of autophagy regulation.
Deregulation of mTOR activity due to perturbation in
upstream signaling events during carcinogenesis can there-
fore have significant impact on autophagy levels and
subsequent tumor outcome. Moreover, mTOR regulation
of autophagy may significantly impact the efficacy of the
growing number of anti-cancer agents targeting the PI3K/
mTOR pathway [47].
Role of autophagy in cancer: context matters
It is increasingly appreciated that the contribution of
autophagy to cancer is extremely complex. There is ample
evidence supporting both tumor promoting and suppressive
functions of autophagy. This apparent paradox can be
reconciled by the fact that the distinct role(s) of autophagy
during cancer progression is/are tumor type, context and
stage specific (Fig. 2). While genetic evidence suggests the
tumor suppressive functions of autophagy act during tumor
initiation, there is also compelling evidence that autophagy
is used as a survival strategy by established tumors to cope
with diverse stresses of the microenvironment that are
encountered during tumor progression and metastasis.
Overall, the importance of autophagy in carcinogenesis, as
well as its potential modulation in cancer therapy, is gaining
significant attention. Autophagy levels, as well as expres-
sion of autophagic molecules, are being used as prognostic
markers for predicting tumor outcome [48–50].
Autophagy in tumor suppression
Since the prototypic functions of autophagy are to recycle
essential nutrients and provide energy for survival during
starvation and stress, it initially seems counterintuitive that
autophagy can act as a potential tumor suppressor mecha-
nism. However, genetic evidence supports that autophagy
can prevent tumor formation. The role of autophagy as a
tumor suppressor was first broached through genetic studies
of beclin1, the mammalian orthologue of yeast ATG6 [51].
Beclin1 was mapped to a tumor susceptibility locus that is
monoallelically deleted in a high percentage of human
breast, ovarian, and prostate cancers; furthermore, analysis
of human tissue samples revealed decreased beclin1
expression in human breast carcinomas compared to normal
breast tissue [51]. Moreover, oncogenes like Akt [36], Ras,
and ERK [52] inhibit autophagy primarily by activating the
mTOR signaling pathway. On the other hand, there is
abundant evidence that tumor suppressors like p53 [44, 46],
PTEN [37], and ARF [53, 54] activate autophagy.
Genetic evidence for tumor suppressor functions
by autophagy-related genes
Beclin1 Beclin1, the mammalian orthologue to yeast
ATG6, was identified due to its interaction with Bcl-2
[55, 56]. Bcl-2 binds to beclin1 and inhibits its autophagic
activity by blocking its interaction with Vps34. Genetic
studies revealed that mice homozygously deleted for
beclin1 die during embryogenesis [57]. Nonetheless, two
groups demonstrated that heterozygous disruption of
beclin1 promoted tumorigenesis in mice, albeit over an
extended latency. Mice lacking a single copy of beclin1
(beclin +/−) developed spontaneous tumors, including
lymphoma, hepatocellular carcinoma, lung adenocarcino-
mas, and mammary hyperplasia [57, 58]. Notably, the loss
of the second allele of beclin did not occur in these tumors,
which strikingly resembled the monoallelic losses original-
ly found in human patients. Thus, these reports provided
the first direct genetic evidence that beclin1/atg6 functions
as a haploinsufficient tumor suppressor. Moreover, ectopic
overexpression of beclin1 in MCF7 mammary carcinoma
cells, which exhibits low beclin1 expression, causes
reduced cancer cell proliferation in vitro and decreased
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this autophagy regulator in tumor suppression [51].
UV irradiation resistance-associated gene UVRAG is a
beclin1-interacting protein that positively regulates autoph-
agy [16]. Like beclin1, UVRAG is monoallelically deleted
in human colon carcinoma [16]. Moreover, frameshift
mutations in the polyadenine tract of the UVRAG gene
are present in gastric carcinomas, and the gastric cancer
cells with the mutations have reduced autophagy activity
[59].
Bif1 Originally identified as a Bax binding protein, Bif1
was recently shown to interact with beclin1 through
UVRAG. It promotes autophagosome membrane curvature
via its N-terminal BAR (Bin/Amphiphysin/Rvs) domain
and thus plays a crucial role in isolation membrane
extension. Bif 1 knockout mice have significantly higher
rate of spontaneous tumors [60] and reduced Bif1 expres-
sion is observed in gastric carcinoma [61].
Other ATG genes ATG4c knockout mice are viable after
birth and do not show higher rate of spontaneous tumors
compared to wild-type animals. However, they have a
higher susceptibility for formation of fibrosarcomas when
exposed to chemical carcinogens [62]. Frameshift muta-
tions in ATG2B, ATG5, and ATG9B were recently reported
in gastric and colorectal carcinomas with high microsatellite
instability, further underlining the tumor suppressor func-
tion of the core autophagic machinery [63].
Mechanisms of tumor suppression by autophagy
Autophagy preventsthe accumulationofdamaged organelles,
oxidative stress, inflammation, and genomic instability A
mounting body of work from Eileen White and colleagues
demonstrates an important role for autophagy in protecting
cells from genotoxic stress and maintaining genome
integrity. This specific tumor suppressor function of
Fig. 2 Schematic depiction of
the tumor suppressive and pro-
tumorigenic roles of autophagy
during cancer progression and
therapy. Tumor suppressive
functions of autophagy include:
(1) eliminating damaged
organelles and mitigating oxida-
tive stress, which prevents
genome instability, and
ultimately, malignant
transformation; (2) promoting
oncogene-induced senescence, a
barrier to malignant
transformation; and (3) prevent-
ing necrosis in apoptosis
deficient cells in response to
metabolic stress, which reduces
pro-tumorigenic inflammation.
Pro-tumorigenic roles for
autophagy include:
(1) promoting tumor cell
survival in response to diverse
micro-enviromental and
chemotherapy-induced stresses,
and (2) protecting cells from
anoikis, which may facilitate
drug-resistance and metastasis.
Further details are provided in
the text
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context of metabolic stress, a condition typically observed
in tumors due to hypoxia and inadequate glucose supply
coupled with increased energy demands of the rapidly
proliferating cells, which leads to extensive cellular damage.
Apoptosis acts as the first line of defense to remove these
damaged cells. However, when apoptosis is reduced or
inactivated, which commonly occurs during tumorigenesis,
the cells rely significantly on autophagy for ATP maintenance
and cellular fitness. In Bcl-2-overexpressing immortalized
mouse mammary epithelial cells and immortalized baby
mouse kidney epithelial cells, loss of one copy of
beclin1 significantly sensitizes cells to metabolic stress
[64, 65]. Paradoxically, in spite of increased survival,
beclin1+/+ cells are less tumorigenic than beclin1+/−
cells. This intriguing outcome is due to the fact that in
autophagy-defective cells, metabolic stress induced signif-
icantly higher DNA double-strand breaks and gene
amplification, as well as the accumulation of damaged
mitochondria and ER chaperones, compared to their wild-
type counterparts. Moreover, p62, a scaffolding protein
involved in signal transduction events, as well as directing
polyubiquitinated proteins and aggregates to autophago-
somal degradation, serves as a critical link between
defective autophagy and tumorigenesis [66]. The aberrant
accumulation of damaged mitochondria and protein
aggregates in autophagy-defective cells leads to elevated
reactive oxygen species (ROS) levels, which causes DNA
damage as well as p62 accumulation. Again p62 accumu-
lation upon metabolic stress leads to ROS generation,
thereby creatinga positivefeedbackloop. Thus,bykeepingin
check the intracellular ROS levels, autophagy serves as a
tumor suppressor function in a cell-autonomous manner.
Importantly, one must recognize that these experiments have
been conducted in cells harboring multiple genetic abnormal-
ities, including the inactivation of the tumor suppressor p53,
which is well-known for its ability to maintain genomic
integrity [67]. Hence, these results are most consistent with
the hypothesis that defective autophagy functions as a
secondary modifier, rather than a fundamental driver, of
genomic damage during tumor progression.
Another potential tumor-suppression mechanism of
autophagy is via inhibition of necrotic cell death of
apoptosis-resistant cells during metabolic stress. Though
decreased viability in the absence of autophagy and
apoptosis should negatively affect tumorigenicity, Degen-
hardt et al. showed that the necrotic cell death causes
macrophage infiltration and proinflammatory cytokine
production and thereby facilitates tumor growth [68].
Remarkably, inflammatory cells infiltrate tumor sites in
response to necrosis resulting from hypoxia and metabolic
stress, both of which commonly affect solid tumors.
Although certain inflammatory cells, such as cytotoxic T
cells and NK cells are anti-metastatic, chronic tumor
inflammation associated with severe hypoxia and metabolic
stress generally favors pro-tumor immunity [69, 70].
Importantly, infiltration of pro-tumor inflammatory media-
tors, like macrophages, correlates with poor clinical
prognosis [71], underscoring the importance of understand-
ing the biological mechanisms by which tumor cells tip the
balance in favor of pro-tumor immunity over tumor
suppressive immunity. Thus, by limiting tumor cell necro-
sis, autophagy may serve as a non-autonomous mechanism
for tumor suppression by preventing leukocyte infiltration
of the primary tumor site.
Autophagy and senescence Oncogene-induced senescence
(OIS), a state of premature permanent cell cycle arrest, is
the first major barrier towards cellular transformation in
response to the mitotic burst induced by oncogenes. It is
characterized by an initial mitotic phase followed by a
transition phase and finally the cell cycle arrest. Recent
studies have identified that the induction and maintenance
of OIS is mediated by an inflammatory network comprised
of IL-6 and IL-8 which function in a cell-autonomous
manner [72]. Interestingly, Young et al. showed that
autophagy is induced during the transition phase of OIS
in an inducible Ras cell culture system [73]. The impor-
tance of autophagy as an essential OIS effector was
established by studies in which significant bypass of
senescence and inhibition of secretion of IL6 and IL8 was
observed upon ATG5 or ATG7 knockdown. Mechanistical-
ly, intracellular recycling associated with autophagy might
provide the amino acids for the synthesis of the secretory
proteins and thereby facilitate OIS. Thus a basal level of
autophagy plays an important role in restricting cell growth
and proliferation during oncogenic stress and potentially
precludes further genomic insults.
Tumor promoting functions for autophagy
Although reduced autophagy is believed to promote tumor
development, a minimal level is believed to be necessary
for the survival of cancer cells. Moreover, increased
autophagy is observed in transformed cells when exposed
to diverse stress. Thus, it is increasingly appreciated that
autophagy provides cancer cells with certain selective
advantages to cope with stress, both in the primary tumor
microenvironment as well as during dissemination and
metastasis. In the following section, we overview three
scenarios in which autophagy-mediated cell survival pro-
motes tumor progression.
Hypoxia Tumor hypoxia, resulting from inadequate tumor
vasculature, is associated with a more malignant phenotype,
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Hypoxic stress selects for cells that are resistant to
apoptosis, as well as poses a major barrier to chemotherapy
and radiotherapy. Degenhardt et al. first showed that
autophagy is induced specifically in the hypoxic core of
tumors where it promotes survival [68]. Further studies
have unveiled the molecular connections between hypoxia
and the induction of autophagy. Hypoxia-inducible factor
1α (HIF-1α), a key transcription factor encoding a plethora
of genes responsible for altered metabolism, angiogenesis,
invasion, metastasis, therapy-resistance in hypoxic tumors
[74], is a positive regulator of autophagy. Bcl-2/adenovirus
E1B 19 kDa-interacting protein (BNIP3), a BH3-only
protein, is a downstream target of HIF-1α and was recently
shown to induce mitophagy and thereby control ROS
production in response to hypoxia [75]. Further mechanistic
studies by Bellot et al. showed that induction of BNIP3 and
BNIP3L in hypoxic cells disrupts the beclin1-Bcl-2
complex, thereby releasing beclin1 to induce autophagy
[76]. Though induction of BNIP3, a proapoptotic protein,
was initially implicated in driving autophagic cell death
[77], more elaborate studies have clearly revealed that
BNIP3-induced autophagy is an adaptive survival response
during prolonged hypoxia [76]. In addition, there is
emerging evidence that various HIF-1α-independent cellu-
lar stress response pathways, like AMPK and UPR, can
also mediate hypoxia-induced autophagy [78, 79].
As the role of autophagy as a key mediator of survival of
hypoxic cells is emerging, the exact mechanisms underlying
thisphenotype remainunclear.Because chronichypoxialeads
to major metabolic perturbations in tumor tissues, one can
postulate that by recycling basic cellular components,
autophagy helps stressed cells cope with the increased
metabolic demand. Nonetheless, further studies are needed
to validate this hypothesis and unveil the interconnections
between hypoxia-driven tumor metabolism and autophagy.
Extracellular matrix detachment Anoikis, or detachment-
induced cell death, serves the homeostatic function of
killing cells that have lost contact with the basement
membrane. Fung et al. showed that autophagy is induced
in non-transformed cells following matrix detachment
which protects cells from anoikis [80]. These experiments
also delineated that autophagy is specifically induced upon
β1 integrin blockade. Moreover, in a three-dimensional
(3D) epithelial culture system, autophagy was significantly
induced in the detached luminal cells and the knockdown of
key autophagy genes resulted in accelerated luminal
clearance. These elaborate in vitro studies proves that
autophagy is instrumental in anoikis resistance, a process
exploited by disseminating tumor cells to survive after
detachment from the primary site as well as while migrating
to distant metastatic sites. Though an interesting hypothesis,
the ability of autophagy to promote tumor dissemination
and metastasis by protecting cells from anoikis must still be
established in relevant in vivo models.
Tumor dormancy After initial regression of the primary
tumor following therapy, cancer can relapse after a long
disease-free period. This occurs due to a small population
of tumor cells that escape therapy and exist as micro-
metastatic cells without any clinical manifestation. Though
viable, these cells are not proliferative and are thus resistant
to conventional chemotherapy that typically targets rapidly
growing cells [81]. Thus, a better understanding of the
molecular events leading to tumor dormancy, as well as the
development of clinically relevant in vivo models are
imperative for identifying suitable treatment options.
Recently, autophagy was shown to be crucial for the
survival of dormant cells in an ovarian cancer model [82].
Lu et al. showed that autophagy supported the survival of a
subset of cells in xenograft ovarian tumors in the face of the
cytotoxic effects of the tumor suppressor aplasia Ras
homolog member I (ARHI). Upon return of more favorable
conditions (i.e. ARHI suppression as observed in clinical
ovarian carcinoma), the tumor regained proliferative poten-
tial and led to rapid regrowth. Apart from this study, there is
no direct evidence for the role of autophagy in tumor
dormancy. Nonetheless, there are numerous scenarios in
which autophagy may promote dormancy. For instance,
tumor dormancy is postulated to be a stress management
mechanism adopted by disseminated tumor cells to cope
with the unfavorable microenvironment by completely
withdrawing from the cell cycle [81]. p27
Kip1, the cyclin
dependent kinase inhibitor involved in G0/G1 cell cycle
arrest, was recently identified as a downstream target of the
energy-sensing LKB1–AMPK pathway and was shown to
induce autophagy and facilitate cell survival in response to
growth factor withdrawal and metabolic stress [83]. Thus,
disseminated tumor cells (DTC) may depend on p27-
mediated autophagy for survival in an inhospitable micro-
environment and to resist chemotherapy. Moreover, studies
in breast cancer models suggest that decreased mitogenic
signaling resulting from impaired integrin and growth
factor signaling may lead to tumor dormancy [84, 85]. As
mentioned above, integrin-signaling blockade is a potent
inducer of autophagy in matrix-detached cells [80], and
thus it can be hypothesized that disrupted integrin
signaling-mediated autophagy induction in DTC can sup-
port and maintain tumor dormancy.
Manipulating autophagy for cancer therapy
Because autophagy plays a crucial role in tumor growth,
one can predict that manipulation of autophagy levels will
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number of studies in preclinical settings indicate that both
the cytoprotective as well as death-inducing properties of
autophagy may be exploited for therapeutic purposes.
Autophagy inhibition as a potential adjuvant therapy in
cancer As discussed above, autophagy is a stress adaptive
response that is upregulated by microenvironmental insults,
including metabolic stress, growth factor withdrawal, and
cellular damage. Similarly, high levels of autophagy are
commonly observed in tumor cells following anti-cancer
treatment. Specifically, anti-neoplastic therapies, including
radiation therapy, chemotherapy (e.g., doxorubicin, temo-
zolomide, camptothecin), histone deacetylase inhibitors,
hormonal therapy (e.g., tamoxifen), targeted anti-cancer
agents (imatinib, trastuzumab) have all been observed to
induce autophagy in various human cancer cell lines
(Table 1). In these contexts, autophagy has been proposed
to be an Achilles heel in cancer therapy, whose disruption
can be a promising strategy to reestablish or increase
sensitivity to therapeutic agents. Indeed, ample evidence
supports this notion in multiple tumor types and in response
to diverse chemotherapeutic agents, highlighting the possi-
bility of targeting autophagy as adjuvant therapy for cancer.
In fact, the effect of inhibiting autophagy in combination
with current anti-cancer therapies has been tested in
multiple tumor models [86].
Pharmacologic inhibition of autophagy The significant
promise of autophagy inhibition in improving clinical
efficacy of chemotherapeutic agents calls for the identifi-
cation and characterization of pharmacological autophagic
inhibitors. Chloroquine (CQ), a well-known anti-malarial
agent, inhibits lysosomal acidification and blocks the
terminal stages of autophagic proteolysis. Remarkably, its
cancer preventive potential was discovered decades ago
when it was shown to reduce the risk of Burkitt's
lymphoma in patients treated for malaria [87]. Currently,
the autophagy inhibitory role of CQ and its analogs is being
avidly investigated for its potential as a cancer therapeutic.
Elegant studies by Amaravadi et al. showed that in a Myc-
induced mouse model of lymphoma, CQ and hydroxy-
chloroquine (HCQ) treatment significantly enhanced the
cytotoxic effects of p53 expression and alkylating agents
[88]. In another study, CQ inhibited spontaneous lympho-
magenesis in Eμ-Myc mice, a model for Burkitt's lympho-
ma, in a p53-dependent manner [89]. While CQ induced
apoptosis in Atg7-deficient Myc-overexpressing MEFs in a
p53-dependent manner, in apotosis-deficient cells, CQ
could induce caspase-independent cell death. Remarkably,
simultaneous inhibition of autophagy and apoptosis attenuat-
ed the cytotoxic effect of CQ, underscoring the prosurvival
roleof autophagy inthiscontext.The promising roleof CQ as
an adjuvant to targeted therapy has also been reported. In
chronic myelocytic leukemia (CML) cell lines, inhibition of
autophagy by CQ potentiates TKI (imantinib)-mediated cell
death [90]. Also, CQ promoted the cytotoxic effects of
SAHA in both imatinib-sensitive and -resistant cell lines of
CML [91].
These studies and the established clinical use of CQ have
prompted clinical trials aimed at investigating the efficacy
of CQ in combination with standard cancer therapies for a
variety of cancers. However, it must be remembered that
the cytotoxic effects of CQ and HCQ might not be solely
due to autophagy inhibition [89]. Thus, development of
autophagy-targeted agents (e.g. ULK1 inhibitors) might be
an attractive strategy for specific autophagy inhibition in
cancer therapy. However, such an approach comes with the
caveat of inhibiting the homeostatic functions of autophagy
in non-transformed cells.
Autophagy-dependent cell death Autophagy-dependent cell
death, also termed type II-programmed cell death, has been
described to be an active death mechanism, where extensive
degradation of cytoplasmic materials beyond a critical point
is believed to drive cell death. However, as the literature
supporting the stress adaptive prosurvival role of autophagy
rapidly expands, it remains controversial whether increased
autophagy observed during a death process serves as an
active death-inducing mechanism versus a failed attempt by
the cell to survive a specific stress or insult [92]. The
potential positive and negative feedback regulation of
autophagy and apoptosis further complicates interpretation.
Moreover, the lack of in vivo validation of cell culture
studies showing autophagy-induced cell death also raises
questions with regard to the physiological relevance of such
a process. Nonetheless, recent studies do show that
autophagy is required for the efficient killing of tumor
cells in certain circumstances (Table 1). Here, we discuss
some of the notable studies describing autophagy-
dependent cell death induced by anti-neoplastic agents in
cancer models typically associated with poor treatment
outcome. Most importantly, these studies largely support a
model in which early and persistent autophagy induction by
a particular agent is required for the subsequent induction
of classical apoptotic pathways.
First, Salazar et al. showed that Δ
9-tetrahydrocannabinol
(THC)-mediated ER stress leads to autophagy-dependent
cell death in glioma cell lines [93]. In this study, THC
treatment induced ER stress and inhibited the AKT/mTOR
pathway. Interestingly, autophagy-induced cell death, both
in vitro and in vivo, was mediated by apoptosis since cells
treated with caspase inhibitors showed the same degree of
death resistance as atg5−/− cells and genetic deletion of
atg5 or RNAi-mediated depletion of atg1 partially pro-
tected cells from apoptosis during THC treatment. More
390 Semin Immunopathol (2010) 32:383–396recently Pardo et al. reported that gemcitabine induced
autophagy and apoptosis in human pancreatic cancer cell
lines. Pharmacological inhibition of autophagy using 3-
MA-impaired gemcitabine induced apoptosis, suggesting
that autophagy promotes cell death via apoptosis [94].
Finally, upon screening for commercially available
immunomodulators for melanoma treatment, Tormo et al.
showed that the double-stranded RNA (dsRNA) mimic,
polyinosine-polycytidylic acid complexed with polyethyle-
neimine ([PIC]
PEI), is a potent inducer of autophagic cell
death [95]. Remarkably, [PIC]
PEI induced recurrent cycles
of endosome and lysosome generation and degradation,
which may reduce the threshold for cell viability and
sensitize the cells to a parallel apoptotic pathway. Impor-
tantly, when autophagy was inhibited via Bafilomycin A,
CQ, or atg5 deletion, cell death was suppressed. Further-
more, cell death was also reduced in melanoma cells upon
pharmacological caspase inhibition or upon genetic deletion
of Bax and Bak, two multi-domain Bcl-2 family members
required for apoptosis; however, such manipulations had no
effect on autophagy induction. Based on these results and
the observed time lag between autophagy induction (2–5h
post-treatment) and final cell collapse (at 24–48 h), the
authors speculated that early and persistent autophagy
induction is required for apoptosis activation at a subse-
quent stage. Overall, these experiments illustrate the
complex interplay between autophagy and apoptosis and
corroborate that both autophagy and apoptosis are needed
to kill cells in certain therapeutic contexts; in such
situations, stimulating autophagy may enhance drug cyto-
toxicity.
Detecting autophagy in human cancer tissues
Despite these exciting experimental findings in cell-based
and mouse models, it is important to recognize that no
direct evidence exists showing that reduced or defective
autophagy is a common requirement for human cancer
initiation. This is primarily because the direct and quanti-
tative detection of autophagy levels in human tumor
samples remains technically intractable. As the importance
of autophagy in carcinogenesis is unveiled, there is a
pressing need for better detection methods and the
identification of suitable markers of autophagy in human
pathology samples [96]. Electron microscopy is still the
most sensitive standard method for this purpose. The
detection of autophagosomes (with intact cytoplasmic
materials and organelles) and autolysosomes (with partially
degraded materials) can be used to identify the different
stages of autophagy by electron microscopy [97]. However,
subclassification of these autophagic ultrastructures is
extremely subjective (e.g., distinction of autolysosomes
from other membrane-enclosed cellular compartments) and
thus requires extensive expertise [98]. Moreover, due to the
elaborate tissue processing steps involved, electron micros-
Table 1 Agents shown to induce autophagy
Role of autophagy Agent Mechanism of action Condition References
Survival Imatinib TKI CML, Glioma [90, 106]
Sorafenib TKI, VEGF inhibitor Colon cancer [107]
Trastuzumab Anti-Her2 Breast cancer [108]
SAHA HDAC inhibitor CML [91]
Tamoxifen ER-antagonist Breast cancer [109]
Deoxyglucose Glycolysis inhibitor Prostate cancer [110]
Arginine deiminase Arginine deprivation Prostate cancer [111]
8-aminoadenosine Nucleoside analog Myeloma [112]
Radiation DNA damage Glioma [113, 114]
Temozolomide DNA damage Glioma [115]
CPT DNA topoisomerase I inhibitor Breast cancer [116]
Death STF-62247 targets VHL-deficient cells VHL-deficient RCC [117]
Gemcitabine Nucleoside analog Pancreatic cancer [94]
THC ER stress Glioma [93]
RAD001 mTOR inhibitor Prostate cancer [118]
[PIC]
PEI immunomodulator Melanoma [95]
CML Chronic myelocytic leukemia, CPT Camptothecin, ER Estrogen receptor, HDAC Histone deacetylase, [PIC]
PEI Polyinosine-polycytidylic acid
complexed with polyethyleneimine, PML promyelocytic leukemia, RCC Renal cell carcinoma, SAHA Suberoylanilide hydroxamic acid,
THC Δ
9-tetrahydrocannabinol, TKI Tyrosine kinase inhibitor, VEGF Vascular endothelial growth factor, VHL Von Hippel-Lindau
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particularly unfeasible in clinical samples.
Therefore, even though electron microscopy remains the
gold standard method for monitoring steady-state levels of
autophagy, use of cell biological and biochemical methods
are more practical approaches in detection and better
quantification of autophagy and autophagic flux. Weakly
basic dyes such as monodansylcadaverine and acridine
orange were initially proposed as specific in vivo marker of
autophagic vacuoles [99]. However, these dyes were later
shown to have high affinity for lysosomes [100], and thus,
their use is no longer recommended. As the molecular
mechanism of autophagy is unraveling, better assays are
being developed for reliable quantitative measurement of
autophagy.
The biggest obstacle in developing methods to detect
bona fide autophagy in clinical material arises from the fact
that autophagy is a multi-step process characterized by the
formation of an autophagosome, followed by its fusion to
the lysosome and degradation of the autophagy substrates
by lysosomal enzymes. As a result, an apparent increase in
the number of autophagosomes observed within a cell can
either mean an increase in the rate of autophagosome
formation or alternatively, a decrease in the rate of
autolysosome formation. Thus, the measurement of a
dynamic process using static methods in clinical samples
poses a fundamental challenge in data interpretation.
LC3 (ATG8) The detection of LC3-II levels by fluores-
cence microscopy, immunoblotting, or immunohistochem-
istry is the most popular method for analysis of autophagy
in cells. As discussed above, LC3-II is the lipidated form of
LC3 resulting from conjugation to phosphotidylethanol-
amine by the ubiquitin-like conjugation system. LC3-II is
incorporated onto both the outer and inner surfaces of the
expanding autophagosome. After fusion with the lysosome,
resident enzymes digest LC3-II associated with the inner
surface, while LC3-II on the outer surface is degraded by
ATG4. Since LC3 remains attached to the autophagosome
until its final fusion with the lysosome, it serves as a useful
and specific marker for the initial steps of autophagy.
Although LC3 has three isoforms (LC3A, LC3B, and
LC3C), LC3B levels correlates best with autophagic
status1, and therefore, antibodies against this isoform are
primarily used for the detection of autophagy.
GFP-LC3-overexpressing cells and transgenic animals
are popular experimental models in which the transition
from diffuse GFP-LC3 cytoplasmic staining to punctate
localization in autophagosomes is used as readout of
autophagy. Though GFP-LC3 puncta is ideally equivalent
to autophagosome number, GFP-LC3 is prone to aggregate
formation. Because these aggregates are difficult to distin-
guish from GFP-LC3 puncta corresponding to bona fide
autophagosomes, the use of these fluorescent strategies can
give rise to false-positive results [101]. Thus, assessing
endogenous LC3-I to LC3-II conversion via immunoblot-
ting is another useful tool to detect autophagy induction;
LC3-II results in a faster migrating band due to high
hydrophobicity of the conjugated PE. Furthermore, the
determination of LC3-II levels in the presence and absence
of chemical inhibitors blocking various steps of autophagy,
(e.g., 3-methyladenine for inhibition of early autophago-
some formation; bafilomycin, chloroquine, or E64D plus
pepstatin A for inhibition of lysosomal activity) helps to
dissect out the status of autophagic flux [102].
Moreover, with the emergence of more sensitive anti-
bodies (Novus NBP1-19 167 against LC3B-II), LC3
immunohistochemical staining is a valuable tool to detect
autophagosome levels in human tissue samples. However,
caution should be exercised while relying on LC3 as the
sole marker of autophagy since in certain cases, for e.g., in
ATG14- or FIP200-deficient mouse fibroblasts, which do
not show any autophagic activity, LC3 II levels are
detected, indicating that LC3 can also be regulated in an
autophagy-independent manner [96]. More importantly, the
detection of punctate LC3 in tissues only provides
information regarding autophagosome number rather than
a readout of autophagic flux. Whereas lysosomal inhibition
can be tractably employed in experimental systems for the
determination of autophagic flux, such manipulations cannot
be applied to clinical samples obtained from patients.
p62/SQSTM Because of the limitations of using LC3 as an
immunohistochemical marker to detect autophagy, there is
a pressing need for alternative markers and techniques to
more reliably measure autophagy in clinical samples. One
attractive candidate is p62/SQSTM, a scaffold protein that
interacts with polyubiquitinated protein aggregates and
targets them to autophagosomes via its interaction with
LC3 [103]. Importantly, p62 protein is degraded in an
autophagy-dependent manner and its expression is inverse-
ly correlated with autophagic activity [96, 104]. Recently, it
was shown that elimination of p62 via autophagy impedes
tumorigenesis [66]. Thus, quantifying p62 levels in tumor
tissues may be a useful marker for autophagy as well as
tumorigenicity. However, because p62 is also regulated at
the transcriptional level, its protein expression can be
regulated independent of autophagy [105].
Overall, although the existing markers to detect and
measure autophagy have proven effective in cell culture
systems, it remains uncertain if such reagents and technique
are suitable or adequate for studies of primary histopathol-
ogy material. Thus, the discovery of additional markers that
can be universally applied for autophagy detection is
critical to utilize autophagy as a potential biomarker as
well as to exploit this pathway therapeutically in cancer.
392 Semin Immunopathol (2010) 32:383–396Concluding remarks
In summary, autophagy has emerged as an important
regulator of tumorigenesis. In light of current evidence, it
is hypothesized that autophagy maintains genomic integrity
and thus prevents tumor initiation. On the other hand, in
established tumors, the stress adaptive property of autoph-
agy improves the cellular fitness of cancer cells and
promotes their survival during disease progression and
during anti-neoplastic therapy. In spite of these current
dogmas, direct evidence establishing this stage-specific role
of autophagy in carcinogenesis is missing. Thus, the
development of mouse cancer models in which autophagy
can precisely be manipulated is imperative to reveal
important answers not only about the precise role of
autophagy in different stages of carcinogenesis but also
how autophagy levels can be regulated for optimal
therapeutic benefits. Finally, there remains a need to
identify robust tissue biomarkers for autophagy in human
cancer specimens.
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